TNF and rheumatoid arthritis: This study, assessing the safety profile including cardiovascular, oncological, and infectious impairments associated with the 5 mg and 10 mg BID of tofacitinib as compared with the anti-TNF drugs, highlighted an increased risk of blood clots in the lungs and death in RA patients with the higher dosage [32].